Valion Bio earnings were -$18.8M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest VBIO earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$7.1M, up 14.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VBIO reported annual earnings of -$8.9M, with 57% growth.
On VBIO's earnings call on Aug 13, 2026, Valion Bio (NASDAQ: VBIO) reported Q2 2026 earnings per share (EPS) of -$54.00, up 1.82% year over year. Total VBIO earnings for the quarter were -$7.10 million. In the same quarter last year, Valion Bio's earnings per share (EPS) was -$55.00.
As of the last Valion Bio earnings report, Valion Bio is currently losing money. Valion Bio's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$18.75 million, a 195.69% increase year over year.
What was VBIO's earnings growth in the past year?
As of Valion Bio's earnings date in Aug 13, 2026, Valion Bio's earnings has grown year over year. VBIO earnings in the past year totalled -$18.75 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.